Skipping cancer: small molecule inhibitors of SKP2-mediated p27 degradation.

The cullin-RING ubiquitin ligase, CRL1(SKP2), directing the degradation of the tumor suppressor p27, is a well validated drug target in a wide variety of human cancers. In this issue of Chemistry & Biology, Wu and colleagues describe first-in-class small molecule inhibitors of CRL1(SKP2)-mediated degradation of p27.